First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is
Tools
Juan, O., Yousaf, N., Popat, S.
(2017)
First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is.
CLINICAL ONCOLOGY, 29 (1).
E1-E4.
ISSN 0936-6555
Full text not available from this repository.
Item Type: | Editorial |
---|---|
Authors (ICR Faculty only): | Popat, Sanjay |
All Authors: | Juan, O., Yousaf, N., Popat, S. |
Additional Information: | ISI Document Delivery No.: EI6ZZ Times Cited: 0 Cited Reference Count: 31 Juan, O. Yousaf, N. Popat, S. NHS O. Juan acknowledges the Spanish Society of Medical Oncology (SEOM) and the CRIS Cancer foundation to support the collaboration with the Royal Marsden Hospital. S. Popat and N. Yousaf acknowledge NHS funding to the Royal Marsden Hospital NIHR-Biomedical Research Centre. 0 ELSEVIER SCIENCE LONDON LONDON CLIN ONCOL-UK |
Uncontrolled Keywords: | RANDOMIZED PHASE-3 TRIAL OPEN-LABEL NETWORK METAANALYSIS PROGRESSION-FREE CHEMOTHERAPY MUTATIONS ERLOTINIB ADENOCARCINOMA AFATINIB GEFITINIB |
Research teams: | Clinical Units > Lung Unit ICR divisions > Clinical Studies > Thoracic Oncology |
Depositing User: | Barry Jenkins |
Date Deposited: | 01 Mar 2017 16:34 |
Last Modified: | 01 Mar 2017 16:34 |
URI: | http://publications.icr.ac.uk/id/eprint/15695 |
Actions (login required)
![]() |
View Item |